{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.8","upperLimit":"25000.0","value":"2440.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"Peak was defined as the maximum post-baseline level of the cytokine.","dispersionType":"Full Range","groups":[{"description":"Participants with relapsed or refractory transplant ineligible DLBCL, PMBCL, or TFL received conditioning chemotherapy (fludarabine 30 mg/m\\^2 IV over 30 minutes and cyclophosphamide 500 mg/m\\^2 IV over 60 minutes) on Days -5, -4, and -3; followed by a single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered IV at a target dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg of BW on Day 0. Participants also received a prophylactic regimen of levetiracetam (750 mg orally or IV twice daily (BID) starting on Day 0) and tocilizumab (8 mg/kg IV over 1 hour (not to exceed 800 mg)) on Day 2).","id":"OG000","title":"Phase 2 (Safety Management Study): Cohort 3"}],"paramType":"MEDIAN","populationDescription":"Participants in the Safety Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline up to Month 3","title":"Pharmacodynamics: Peak Level of Cytokine (Ferritin) in Serum (Phase 2 Cohort 3)","type":"SECONDARY","unitOfMeasure":"ng/mL"}